vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and Liberty Energy Inc. (LBRT). Click either name above to swap in a different company.
Elanco Animal Health Inc is the larger business by last-quarter revenue ($1.1B vs $1.0B, roughly 1.1× Liberty Energy Inc.). Liberty Energy Inc. runs the higher net margin — 2.2% vs -24.1%, a 26.3% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 4.5%). Over the past eight quarters, Elanco Animal Health Inc's revenue compounded faster (-2.6% CAGR vs -6.2%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Liberty Energy Inc. is a North American energy services provider specializing in hydraulic fracturing and well completion solutions for oil and gas operators. It serves clients across major U.S. shale basins, offering low-emission equipment and tailored support to optimize well productivity.
ELAN vs LBRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.0B |
| Net Profit | $-276.0M | $22.6M |
| Gross Margin | 51.5% | — |
| Operating Margin | -22.6% | 2.2% |
| Net Margin | -24.1% | 2.2% |
| Revenue YoY | 12.2% | 4.5% |
| Net Profit YoY | -3350.0% | — |
| EPS (diluted) | $-0.55 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.0B | ||
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $947.4M | ||
| Q2 25 | $1.2B | $1.0B | ||
| Q1 25 | $1.2B | $977.5M | ||
| Q4 24 | $1.0B | $943.6M | ||
| Q3 24 | $1.0B | $1.1B | ||
| Q2 24 | $1.2B | $1.2B |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $-276.0M | $13.7M | ||
| Q3 25 | $-34.0M | $43.1M | ||
| Q2 25 | $11.0M | $71.0M | ||
| Q1 25 | $67.0M | $20.1M | ||
| Q4 24 | $-8.0M | $51.9M | ||
| Q3 24 | $364.0M | $73.8M | ||
| Q2 24 | $-50.0M | $108.4M |
| Q1 26 | — | — | ||
| Q4 25 | 51.5% | 20.6% | ||
| Q3 25 | 53.4% | 18.7% | ||
| Q2 25 | 57.5% | 22.1% | ||
| Q1 25 | 57.3% | 22.1% | ||
| Q4 24 | 50.9% | 21.4% | ||
| Q3 24 | 52.2% | 26.2% | ||
| Q2 24 | 58.2% | 27.9% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -22.6% | 1.9% | ||
| Q3 25 | -4.4% | -0.3% | ||
| Q2 25 | 2.0% | 3.6% | ||
| Q1 25 | 5.0% | 1.9% | ||
| Q4 24 | -5.0% | 2.6% | ||
| Q3 24 | 54.3% | 9.4% | ||
| Q2 24 | -2.7% | 12.2% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -24.1% | 1.3% | ||
| Q3 25 | -3.0% | 4.5% | ||
| Q2 25 | 0.9% | 6.8% | ||
| Q1 25 | 5.6% | 2.1% | ||
| Q4 24 | -0.8% | 5.5% | ||
| Q3 24 | 35.3% | 6.5% | ||
| Q2 24 | -4.2% | 9.3% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $-0.55 | $0.08 | ||
| Q3 25 | $-0.07 | $0.26 | ||
| Q2 25 | $0.02 | $0.43 | ||
| Q1 25 | $0.13 | $0.12 | ||
| Q4 24 | $-0.01 | $0.31 | ||
| Q3 24 | $0.73 | $0.44 | ||
| Q2 24 | $-0.10 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $699.1M |
| Total DebtLower is stronger | $3.9B | $7.1M |
| Stockholders' EquityBook value | $6.5B | $1.9B |
| Total Assets | $13.4B | $4.4B |
| Debt / EquityLower = less leverage | 0.60× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $699.1M | ||
| Q4 25 | $545.0M | $27.6M | ||
| Q3 25 | $505.0M | $13.5M | ||
| Q2 25 | $539.0M | $19.6M | ||
| Q1 25 | $487.0M | $24.1M | ||
| Q4 24 | $468.0M | $20.0M | ||
| Q3 24 | $490.0M | $23.0M | ||
| Q2 24 | $416.0M | $30.0M |
| Q1 26 | — | $7.1M | ||
| Q4 25 | $3.9B | $246.6M | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.1B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | $190.5M | ||
| Q3 24 | $4.4B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $6.5B | $2.1B | ||
| Q3 25 | $6.7B | $2.1B | ||
| Q2 25 | $6.8B | $2.0B | ||
| Q1 25 | $6.4B | $2.0B | ||
| Q4 24 | $6.1B | $2.0B | ||
| Q3 24 | $6.5B | $2.0B | ||
| Q2 24 | $5.9B | $1.9B |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $13.4B | $3.6B | ||
| Q3 25 | $13.6B | $3.5B | ||
| Q2 25 | $13.7B | $3.4B | ||
| Q1 25 | $12.9B | $3.4B | ||
| Q4 24 | $12.6B | $3.3B | ||
| Q3 24 | $13.3B | $3.3B | ||
| Q2 24 | $13.8B | $3.2B |
| Q1 26 | — | 0.00× | ||
| Q4 25 | 0.60× | 0.12× | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.61× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.70× | 0.10× | ||
| Q3 24 | 0.67× | — | ||
| Q2 24 | 0.96× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | 13.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $195.4M | ||
| Q3 25 | $219.0M | $51.5M | ||
| Q2 25 | $237.0M | $170.6M | ||
| Q1 25 | $-4.0M | $192.1M | ||
| Q4 24 | $177.0M | $177.3M | ||
| Q3 24 | $162.0M | $244.5M | ||
| Q2 24 | $200.0M | $248.2M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $-10.0M | ||
| Q3 25 | $127.0M | $-67.2M | ||
| Q2 25 | $180.0M | $33.1M | ||
| Q1 25 | $-69.0M | $58.2M | ||
| Q4 24 | $130.0M | $-26.2M | ||
| Q3 24 | $120.0M | $77.9M | ||
| Q2 24 | $166.0M | $112.2M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | -1.0% | ||
| Q3 25 | 11.2% | -7.1% | ||
| Q2 25 | 14.5% | 3.2% | ||
| Q1 25 | -5.8% | 6.0% | ||
| Q4 24 | 12.7% | -2.8% | ||
| Q3 24 | 11.7% | 6.8% | ||
| Q2 24 | 14.0% | 9.7% |
| Q1 26 | — | 13.1% | ||
| Q4 25 | 5.4% | 19.8% | ||
| Q3 25 | 8.1% | 12.5% | ||
| Q2 25 | 4.6% | 13.2% | ||
| Q1 25 | 5.4% | 13.7% | ||
| Q4 24 | 4.6% | 21.6% | ||
| Q3 24 | 4.1% | 14.6% | ||
| Q2 24 | 2.9% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 14.28× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | 21.55× | 2.40× | ||
| Q1 25 | -0.06× | 9.55× | ||
| Q4 24 | — | 3.42× | ||
| Q3 24 | 0.45× | 3.31× | ||
| Q2 24 | — | 2.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
LBRT
Segment breakdown not available.
